Corbus Pharmaceuticals

Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate

Antonette Ho2025-02-16T17:18:58-05:00On Friday, Corbus Pharmaceuticals Holdings, Inc. announced that data from its US and UK first-in-human dose escalation clinical study of CRB-701 (SYS6002) were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium. The Phase 1 Western dose escalation study enrolled participants with metastatic urothelial cancer (mUC) and other solid tumors associated with Nectin-4 expression. These included several tumor types not previously explored in China. Read more >>

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

Antonette Ho2025-02-15T23:53:36-05:00Corbus Pharmaceuticals Holdings, Inc., today announced that the abstract for its first-in-human dose escalation clinical study conducted in the United States and Europe (“Western study”) of CRB-701 (SYS6002) has been released. Read more >>

Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025

Antonette Ho2025-01-23T02:52:09-05:00Corbus Pharmaceuticals Holdings, Inc., today announced data from its first-in-human dose escalation clinical study conducted in the United States and the United Kingdom (“Western study”) of CRB-701 (SYS6002) will be presented at the 2025American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), to be held in San Francisco, CA February 13–15, 2025. The poster is titled Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701 (SYS6002) in US And UK Patients with Urothelial Cancer and other Solid...

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

Antonette Ho2025-01-23T03:11:19-05:00Corbus Pharmaceuticals Holdings, Inc., an oncology and obesity company with a diversified portfolio, today announced the dosing of the first patient in the Phase 1 portion of the clinical study of CRB-601 for the treatment of patients with advanced solid tumors (NCT06603844). CRB-601 is a monoclonal antibody targeting latent TGFβ activation-by blocking the integrin αVβ8. Pre-clinical data has demonstrated that CRB-601 overcomes tumor immune exclusion and enhances the activity of immune checkpoint inhibitors in vivo. Read more >>

Corbus Pharmaceuticals Receives Fast Track from FDA for Cervical Cancer Treatment

Antonette Ho2025-02-15T23:45:10-05:00Corbus Pharmaceuticals received a fast-track designation from the Food and Drug Administration for its treatment of relapsed or refractory metastatic cervical cancer. The Norwood, Mass., oncology company on Tuesday said the treatment, CRB-701, is being tested for safety and efficacy in a Phase 1 clinical trial in patients with advanced solid tumors known to be associated with high Nectin-4 expression. CRB-701 targets Nectin-4, which is a cell adhesion protein that is over-expressed in many types of human cancers. Corbus said...

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Antonette Ho2024-10-26T09:34:15-04:00Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today that it has completed enrollment of the dose escalation part of its bridging Phase 1 clinical trial of CRB-701 (SYS6002). The dose escalation part of this open label study (NCT06265727) is being conducted in the US and the UK. The three-part Phase 1 trial is evaluating the safety, pharmacokinetics and efficacy of CRB-701 in patients with advanced solid tumors...

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Antonette Ho2024-04-06T15:17:16-04:00Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, announced today the first patient in the U.S. has been dosed in the Phase 1 clinical trial of CRB-701 (SYS6002), a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4. The Phase 1 portion of the open label study design (NCT06265727), being conducted in the U.S. and Europe, will evaluate the safety, efficacy and pharmacokinetics (PK) of CRB-701 in participants with advanced solid tumors associated with...

Corbus Pharmaceuticals Names Dominic Smethurst CMO

Antonette Ho2024-03-10T00:38:38-05:00Corbus Pharmaceuticals Holdings, Inc. (CRBP) Wednesday announced that it has appointed Dominic Smethurst as its chief medical officer. Smethurst has over 20 years of experience in the pharmaceutical and biotechnology sector, including the UK's National Health Service. Most recently he was the CMO of Bicycle Therapeutics. In pre-market activity, Corbus shares are trading at $26.75, up 2.61% on the Nasdaq. Read more >>

Corbus Pharmaceuticals Announces Pricing of Public Offering

Antonette Ho2024-02-02T16:08:54-05:00Corbus Pharmaceuticals Holdings, Inc., a precision oncology company with a diversified portfolio, today announced the pricing of an underwritten public offering of 4,325,000 shares of its common stock at a public offering price of $19.00 per share, for a total public offering size of approximately $82.2 million, before deducting underwriting discounts and estimated offering expenses. In addition, Corbus has granted the underwriters a 30-day option to purchase up to an additional 648,750 shares of its common stock on the same...

Corbus Pharma’s IND Application Gets FDA Clearance For Investigational Drug CRB-601

Antonette Ho2024-01-18T20:38:09-05:00Corbus Pharmaceuticals Holdings, Inc.  Tuesday announced FDA clearance for its investigational new drug or IND application of CRB-601, a TGFß blocking monoclonal antibody targeting the integrin avß8. Read more >>